GoPro, Inc. (NASDAQ:GPRO) on July 31 announced financial results for its second quarter ended June 30, 2014. Revenue in the second quarter of 2014 was $244.6 million, up 38.1% compared to the $177.1 million reported in the second quarter of 2013. Non-GAAP net income in the second quarter of 2014 was $11.8 million or $0.08 per diluted share, compared to a net loss of ($3.2) million or ($0.03) per diluted share in the second quarter of 2013 and net income of $14.3 million or $0.10 per diluted share in the first quarter of 2014. GoPro recorded a GAAP net loss in the second quarter of 2014 of $(19.8) million or $(0.24) per diluted share. GoPro, Inc. (NASDAQ:GPRO) belongs to Services sector. Its net profit margin is 3.60% and weekly performance is 19.66%. On last trading day company shares ended up $51.80. GoPro, Inc. (NASDAQ:GPRO) distance from 50-day simple moving average (SMA50) is 24.66%.

Amicus Therapeutics (NASDAQ:FOLD) VP Jayne Gershkowitz unloaded 5,000 shares of Amicus Therapeutics stock on the open market in a transaction dated Wednesday, August 27th. The shares were sold at an average price of $7.00, for a total value of $35,000.00. Following the completion of the sale, the vice president now directly owns 50,000 shares in the company, valued at approximately $350,000. Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares fell -1.10% in last trading session and ended the day at $7.19. FOLD return on assets is -53.70%. Amicus Therapeutics, Inc. (NASDAQ:FOLD) quarterly performance is 192.28%.

ABIOMED news, CEO Michael R. Minogue unloaded 82,383 shares of ABIOMED stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $26.30, for a total transaction of $2,166,672.90. On 29 August, ABIOMED, Inc. (NASDAQ:ABMD) shares fell -0.08% and was closed at $26.05. ABMD EPS growth in last 5 year was 17.10%. ABIOMED, Inc. (NASDAQ:ABMD) year to date (YTD) performance is -2.58%.

Veracyte, Inc. (NASDAQ:VCYT) on 13 Aug 2014 reported financial results for the second quarter ended June 30, 2014, and provided an update on business progress. For the second quarter of 2014, revenue was $8.7 million, an increase of 71%, compared to $5.1 million for the second quarter of 2013. Revenue for the six months ended June 30, 2014 was $16.2 million, compared to $9.5 million for the same period in 2013, also an increase of 71%.Veracyte, Inc. (NASDAQ:VCYT) ended the last trading day at $12.56. Company weekly volatility is calculated as 3.52%and price to cash ratio as 4.65. Veracyte, Inc. (NASDAQ:VCYT) showed a weekly performance of 0.88%.

Brown Shoe Co. said its fiscal second-quarter profit rose 18% after its wholesale business and Famous Footwear chain reported higher sales. The company’s per-share earnings outpaced market expectations, leading Brown Shoe to raise its outlook for the year. It now expects earnings between $1.50 and $1.60 a share, up from its prior forecast of $1.47 to $1.57 a share. It backed its revenue outlook. Brown Shoe Co. Inc. (NYSE:BWS) shares fell -0.83% in last trading session and ended the day on $29.84. BWS Gross Margin is 40.40% and its return on assets is 5.60%. Brown Shoe Co. Inc. (NYSE:BWS) quarterly performance is 7.49%.